XL 188 is a potent and selective USP7 inhibitor with IC50 values of 90 nM and 193 nM for USP7 full-length and catalytic domain enzyme, respectively. XL 188 can be used in research of cancer.
XL 188 (1-20 μM; 16 h; MCF7 cells) promotes USP7 dependent loss of HDM2 and increase of p53 and p21[1].
References:
[1]. Stolte B, et, al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med. 2018 Aug 6;215(8):2137-2155.